Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 5, 2012, Pages 536-542

  Guo, Yingjie ^a   Hu, Cheng ^a   He, Xiaojing ^b   Qiu, Feng ^b   Zhao, Limei ^b  

^a JILIN UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

CYP2C9; Epilepsy; Genetic polymorphisms; UGT1A6; UGT2B7; Valproic acid

Indexed keywords

CYTOCHROME P450 2C9; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 2B7; VALPROIC ACID;

ARTICLE; CHILD; CHINESE; COHORT ANALYSIS; CYP2C9 GENE; DNA SEQUENCE; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; UGT1A6 GENE; UGT2B7 GENE;

EID: 84864404183     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-NT-144     Document Type: Article

References (28)

1. Chadwick, D. W.: Concentration-effect relationships of valproic acid. Clin. Pharmacokinet., 10: 155-163 (1985).
2. DeVane, C. L.: Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacol. Bull., 37 (Suppl 2): 25-42 (2003).
3. Ebner, T. and Burchell, B.: Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab. Dispos., 21: 50-55 (1993).
4. Kiang, T. K., Ho, P. C., Anari, M. R., Tong, V., Abbott, F. S. and Chang, T. K.: Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol. Sci., 94: 261-271 (2006).
5. Xing, Y., Yang, L., Wang, L., Shao, L., Wei, Z., Xuan, J., Li, J., Qin, S., Shu, A., He, L. and Xing, Q.: Systematic screening for polymorphisms within the UGT1A6 gene in three Chinese populations and function prediction through structural modeling. Pharmacogenomics, 10: 741-752 (2009).
6. Krishnaswamy, S., Hao, Q., Al-Rohaimi, A., Hesse, L. M., von Moltke, L. L., Greenblatt, D. J. and Court, M. H.: UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J. Pharmacol. Exp. Ther., 313: 1340-1346 (2005).
7. Nagar, S., Zalatoris, J. J. and Blanchard, R. L.: Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics, 14: 487-499 (2004).
8. Lin, G. F., Guo, W. C., Chen, J. G., Qin, Y. Q., Golka, K., Xiang, C. Q., Ma, Q. W., Lu, D. R. and Shen, J. H.: An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidineexposed workers in China. Toxicol. Sci., 85: 502-506 (2005).
9. Bhasker, C. R., McKinnon, W., Stone, A., Lo, A. C., Kubota, T., Ishizaki, T. and Miners, J. O.: Genetic polymorphism of UDPglucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics, 10: 679-685 (2000).
10. Court, M. H.: Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab. Rev., 42: 209-224 (2010).
11. Thibaudeau, J., Lépine, J., Tojcic, J., Duguay, Y., Pelletier, G., Plante, M., Brisson, J., Têtu, B., Jacob, S., Perusse, L., Bélanger, A. and Guillemette, C.: Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res., 66: 125-133 (2006).
12. Yang, J. Q., Morin, S., Verstuyft, C., Fan, L. A., Zhang, Y., Xu, C. D., Barbu, V., Funck-Brentano, C., Jaillon, P. and Becquemont, L.: Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam. Clin. Pharmacol., 17: 373-376 (2003).
13. Lee, C. R., Goldstein, J. A. and Pieper, J. A.: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 12: 251-263 (2002).
14. Amini-Shirazi, N., Ghahremani, M. H., Ahmadkhaniha, R., Mandegary, A., Dadgar, A., Abdollahi, M., Shadnia, S., Pakdaman, H. and Kebriaeezadeh, A.: Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicol. Mech. Methods, 20: 452-457 (2010).
15. Chung, J. Y., Cho, J. Y., Yu, K. S., Kim, J. R., Lim, K. S., Sohn, D. R., Shin, S. G. and Jang, I. J.: Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin. Pharmacol. Ther., 83: 595-600 (2008).
16. Ho, P. C., Abbott, F. S., Zanger, U. M. and Chang, T. K.: Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J., 3: 335-342 (2003).
17. Sun, Y. P., Tan, L., Wang, Y. and Song, J. H.: Effect of UGT1A6 genetic polymorphisms on the metabolism of sodium valproate. Zhonghua Yi Xue Za Zhi, 87: 2033-2035 (2007).
18. Tan, L., Yu, J. T., Sun, Y. P., Ou, J. R., Song, J. H. and Yu, Y.: The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin. Neurol. Neurosurg., 112: 320-323 (2010).
19. Wang, Y., Gao, L., Liu, Y. P., Huang, N. N., Xu, S. J. and Ma, D. J.: Effect of UGTIA6 A541G genetic polymorphism on the metabolism of valproic acid in Han epileptic children from Henan. Zhongguo Dangdai Erke Zazhi, 12: 429-432 (2010).
20. Hung, C. C., Ho, J. L., Chang, W. L., Tai, J. J., Hsieh, T. J., Hsieh, Y. W. and Liou, H. H.: Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics, 12: 1107-1117 (2011).
21. Clements, D. N., Wood, S., Carter, S. D. and Ollier, W. E.: Assessment of the quality and quantity of genomic DNA recovered from canine blood samples by three different extraction methods. Res. Vet. Sci., 85: 74-79 (2008).
22. Tankanitlert, J., Morales, N. P., Howard, T. A., Fucharoen, P., Ware, R. E., Fucharoen, S. and Chantharaksri, U.: Effects of combined UDP-glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on paracetamol pharmacokinetics in beta-thalassemia/HbE. Pharmacology, 79: 97-103 (2007).
23. Wang, S. L., Huang, J., Lai, M. D. and Tsai, J. J.: Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics, 5: 37-42 (1995).
24. Argikar, U. A. and Remmel, R. P.: Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab. Dispos., 37: 229-236 (2009).
25. Strassburg, C. P., Strassburg, A., Kneip, S., Barut, A., Tukey, R. H., Rodeck, B. and Manns, M. P.: Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut, 50: 259-265 (2002).
26. Miyagi, S. J. and Collier, A. C.: The development of UDPglucuronosyltransferases 1A1 and 1A6 in the pediatric liver. Drug Metab. Dispos., 39: 912-919 (2011).
27. Argikar, U. A. and Remme, R. P.: Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab. Dispos., 37: 229-236 (2009).
28. Jiang, D., Bai, X., Zhang, Q., Lu, W., Wang, Y., Li, L. and Müller, M.: Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. Eur. J. Clin. Pharmacol., 65: 1187-1193 (2009).